Summary: Host: Caitlin Costello, MD <br> Guest: Sagar Lonial, MD, FACP <br> <p><span xml:lang="EN-US" data-contrast="none">Bispecific antibodies are the newest immunotherapies approved for heavily pretreated relapsed/refractory myeloma, and they are shown to double response rates. Are you ready to use them in your practice? Join Drs. Costello and </span><span xml:lang="EN-US" data-contrast="none">Lonial</span><span xml:lang="EN-US" data-contrast="none"> as they explore a case study that </span><span xml:lang="EN-US" data-contrast="none">demonstrates</span><span xml:lang="EN-US" data-contrast="none"> how to select patients, prepare them for treatment, and effectively manage treatment-related side effects.</span> </p>
